# Advances and Challenges in KRAS Mutation Detection and Clinical Implications

## TL;DR

This paper reviews methods for detecting KRAS mutations in cancer, highlighting recent drug developments and the importance of accurate diagnosis for personalized treatment.

## Contribution

A comprehensive overview of KRAS mutation detection methods, comparing their clinical applicability and diagnostic performance.

## Key findings

- KRAS mutations are major drivers of cancer progression and resistance to therapy.
- Recent advances have led to the development of selective KRAS inhibitors.
- Accurate detection methods are crucial for personalized cancer treatment.

## Abstract

Mutations in the RAS signaling pathway, especially in the KRAS oncogene, are major drivers of cancer progression, therapy resistance, and poor clinical outcomes. For decades KRAS was considered undruggable, but recent advances have produced selective KRAS inhibitors, creating new opportunities for personalized cancer treatment. Accurate identification of KRAS mutations is therefore essential for selecting targeted therapies, predicting drug response, and guiding clinical decisions. This review provides an overview of established and emerging KRAS detection methods, comparing their sensitivity, specificity, cost, and clinical applicability. The goal is to support researchers and clinicians in improving cancer diagnostics and optimizing patient care.

Aberrant activation of the RAS signaling pathway is a halmark of various cancers. This activation, is often caused by mutations in RAS genes or other pathway components and, drivesi uncontrolled cell growth and proliferation. Studies have demonstrated that certain codon mutations can significantly influence the clinical outcomes of cancer patients. Historically, KRAS was considered “undruggable”; however, recent advancements in drug discovery have led to the development of promising KRAS inhibitors. Accurately identifying the specific type of KRAS mutation in a patient is essential for making optimal treatment decisions. Several methods have been developed for detecting KRAS mutations to address this need, focusing on creating robust, rapid, sensitive, accurate, and cost-effective approaches, particularly for point-of-care applications. Starting with the Ras family and RASopathies, this review provides a comprehensive overview of KRAS mutation detection methods, ranging from research-use-only techniques to in vitro diagnostic-certified tests. Published results are critically evaluated in terms of accuracy, sensitivity, cost, throughput, and suitability for various sample types and clinical settings. This, offers researchers and clinicians an up-to-date resource for.